OSCR
Oscar Health, Inc.
OSCR's fundamentals are strong: revenue grew 55% and its operating margin went from −1.9% to 5.4%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
PGEN
Precigen, Inc.
There isn't enough reported data to score PGEN yet.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PGEN Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Healthy | |
| Unavailable | |
| Unavailable |
PGEN's profitability is currently healthy. There isn't enough data to rate its revenue, cash flow and balance sheet.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over PGEN in the historical PE scenario, which offers more potential upside but is not a forecast.
PGEN PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 7.2x | $4.66 | — |
| Cheap | 7.9x | $0.55 | -88% |
| Fair | 9.5x | $0.66 | -86% |
| Expensive | 14x | $0.98 | -79% |
| Current | 67x | $4.66 | — |
Historical ranges are pointers, not guarantees.
PGEN's PE is 67x, but its earnings don't support one, so it isn't a reliable read right now.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PGEN Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Returning to profit | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect PGEN to return to profit, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PGEN on earnings, with more consistent year-over-year improvement.
PGEN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.65 | +829% |
| Q3 2026 | $0.07 | +$1.45 |
| Q2 2026 | -$1.07 | -$0.66 |
| Q1 2026 | -$1.21 | -$0.66 |
| Q4 2025 | -$1.37 | -$0.90 |
| Q3 2025 | -$1.38 | -$0.83 |
| Q2 2025 | -$0.41 | +$0.13 |
| Q1 2025 | -$0.55 | -$0.16 |
| Q4 2024 | -$0.47 | -$0.08 |
PGEN has returned to profit: it earned $0.07 per share over the past year, after losing money the year before.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
PGEN has the stronger quarterly revenue trend. Revenue is up 72% for OSCR versus up 3,906% for PGEN.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PGEN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1.8M | -39% |
| Q1 2023 | $1.9M | -94% |
| Q4 2022 | $1.8M | -93% |
| Q3 2022 | $16.7M | -22% |
| Q2 2022 | $2.9M | -91% |
| Q1 2022 | $32M | +31% |
| Q4 2021 | $24.2M | +25% |
| Q3 2021 | $21.6M | -8.6% |
PGEN's revenue is growing: $74M last quarter, up 3906% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 52% | N/A |
| Q2 2026 | 41% | N/A |
| Q1 2026 | -26% | N/A |
| Q2 2023 | -1154% | -255 points |
| Q1 2023 | -1231% | -1171 points |
| Q4 2022 | -1257% | -1154 points |
| Q3 2022 | -46% | +93 points |
| Q2 2022 | -898% | -838 points |
PGEN has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over PGEN on cash generation, producing positive trailing cash flow while its opponent burns cash.
PGEN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $11.4M | +$40.9M |
| Q2 2026 | -$18.2M | +$1.7M |
| Q1 2026 | -$44.1M | -$27.1M |
| Q4 2025 | -$23.5M | -$14.2M |
| Q3 2025 | -$29.5M | -$5.8M |
| Q2 2025 | -$19.9M | +$5.5M |
| Q1 2025 | -$16.9M | +$1.5M |
| Q4 2024 | -$9.3M | +$7.5M |
PGEN has burned cash in almost every quarter: −$74M over the past year, against −$76M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over PGEN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PGEN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.8% | +7.5M shares |
| 1 year | +37% | +114M shares |
| 3 years | +69% | +173M shares |
| 5 years | +112% | +222M shares |
| Available history | +173% | +267M shares |
PGEN has 421M diluted shares, up 37% from a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
PGEN Net Leverage
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PGEN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 42.6 | Neutral |
| Stochastic | 23.8 | Neutral |
PGEN's weekly RSI is 43 (neutral) and its Stochastic is 24 (neutral).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over PGEN on valuation relative to its sector.
PGEN PE vs Healthcare Sector
| Metric | PGEN | Sector median | Relative |
|---|---|---|---|
| PE | 67x | 26x | 158% above |
| PE % | 100 | 29 | 71 pts above |
PGEN is trading at 67x earnings, a 158% premium to the Healthcare sector's median of 26x, though its earnings don't support one.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PGEN on trend strength, trading above more of its moving averages.
PGEN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.59 | 29% below |
| 20 week MA | $6.48 | 28% below |
| 50 week MA | $5.10 | 8.6% below |
| 100 week MA | $3.68 | 27% above |
| 200 week MA | $2.48 | 88% above |
PGEN has pulled back, but its long-term trend is still up: it's below its 8-, 20- and 50-week averages, but 88% above its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PGEN on returns for 2026, with the stronger performance.
PGEN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $5.74 | $10.0 | +75% |
| 2021 | $10.0 | $4.10 | -59% |
| 2022 | $4.10 | $1.40 | -66% |
| 2023 | $1.40 | $1.34 | -4.3% |
| 2024 | $1.34 | $0.73 | -46% |
| 2025 | $0.73 | $4.16 | +470% |
| 2026 YTD | $4.16 | $4.66 | +12% |
PGEN's yearly returns have swung widely, from +470% in 2025 to −66% in 2022. It's up 12% so far in 2026.